Researchers sought to measure adherence to topical management regimens among patients with HFSR due to treatment with regorafenib.
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
Despite overall decline or stabilization, increase seen for young adults in some high-income countries.
For those diagnosed with lung cancer, CRC, higher CRF tied to lower risk for subsequent death
Prevalence higher for advanced adenomas, advanced serrated lesions, serrated polyposis syndrome.